SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Martin Bigler, Jürg Bernhard et al.|BMC Cancer|2016Cited by 46
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Christoph Rochlitz, Khalil Zaman, Thomas Ruhstaller et al.|Annals of Oncology|2010Cited by 26
Capecitabine and Vinorelbine as First-Line Treatment in Elderly Patients (≥65 Years) with Metastatic Breast CancerDagmar Hess, Karin Ribi, Dieter Köberle et al.|Oncology|2007Cited by 24
Trastuzumab (Herceptin®) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patientsMarc Salzberg, Christoph Rochlitz, Markus Borner et al.|European Journal of Cancer|2006Cited by 22
Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding TrialCatrina Uhlmann, Stefan Aebi, Pierluigi Ballabeni et al.|Oncology|2004Cited by 16